-
公开(公告)号：EP3489260B1
公开(公告)日：2020-12-02
申请号：EP19150601.3
申请日：2008-02-22
-
公开(公告)号：EP3148575B1
公开(公告)日：2019-08-21
申请号：EP15803012.2
申请日：2015-06-02
发明人： OH, Sangkon , KANE, Bob , ZURAWSKI, Gerard
-
公开(公告)号：EP2966091B1
公开(公告)日：2018-04-25
申请号：EP15182056.0
申请日：2009-07-16
发明人： BANCHEREAU, Jacques F. , ZURAWSKI, Gerard , FLAMAR, Anne-laure , COBB, Amanda , MEAD, Holly , MONTES, Monica
CPC分类号： C07K14/005 , A61K39/12 , A61K39/21 , A61K47/646 , A61K47/6843 , A61K47/6849 , C07K16/2878 , C07K2319/01 , C07K2319/035 , C07K2319/30 , C07K2319/33 , C12N2740/16222 , C12N2740/16234 , C12N2740/16322 , C12N2740/16334
摘要： The present invention relates to an agonistic anti-CD40 antibody which is shown to bind and activate CD40. In particular secretion of high levels of IL-12p40 by dendritic cells (DC) is demonstrated.
-
公开(公告)号：EP2688592A1
公开(公告)日：2014-01-29
申请号：EP12765865.6
申请日：2012-03-26
IPC分类号： A61K39/395 , A61P31/12 , C07K16/46 , A61K39/29 , A61P37/04 , C12N5/0784
CPC分类号： C12N5/0639 , A61K39/12 , A61K39/29 , A61K2039/6056 , C07K14/005 , C07K16/2851 , C07K16/2878 , C07K2319/00 , C07K2319/33 , C12N2770/24222 , C12N2770/24234
摘要： Compositions comprising viral antigens and antigenic peptides corresponding to or derived from Hepatitis C virus (HCV) proteins or fragments thereof, fused to heavy and/or light chain of antibodies, or fragments thereof specific for dendritic cells (DCs) are described herein. Included herein are immunostimulatory compositions (HCV vaccines, HCV antigen presenting dendritic cells, etc.) and methods for increasing effectiveness of HCV antigen presentation by an antigen presenting cell, for a treatment, a prophylaxis or a combination thereof against hepatitis C in a human subject, and methods of providing immunostimulation by activation of one or more dendritic cells, methods to treat or prevent hepatitis C.
-
5.发明公开DENDRITIC CELL IMMUNORECEPTORS (DCIR)-MEDIATED CROSSPRIMING OF HUMAN CD8+ T CELLS 审中-公开树突状细胞免疫受体交换交叉吸人CD8 + T细胞
公开(公告)号：EP2566518A1
公开(公告)日：2013-03-13
申请号：EP11778288.8
申请日：2011-05-04
CPC分类号： A61K39/385 , A61K38/162 , A61K2039/6056 , C07K16/2851 , C07K2317/76 , C07K2319/00 , Y02A50/39 , Y02A50/403 , Y02A50/41 , Y02A50/412 , Y02A50/414
摘要： Immunostimulatory compositions and methods comprising an ITIM motif-containing DC immunoreceptor (DCIR) to mediate potent crosspresentation are described herein. The inventors evaluated human CD8+ T cell responses generated by targeting antigens to dendritic cells (DCs) through various lectin receptors. A single exposure to a low dose of anti-DCIR-antigen conjugate initiated antigen-specific CD8+ T cell immunity by all human DC subsets including ex vivo generated DCs, skin-isolated Langerhans cells and blood mDCs and pDCs. Enhanced specific CD8+ T cell responses were observed when antigens like, FluMP, MART-1, viral (HIV gag), etc. were delivered to the DCs via DCIR, compared to those induced by a free antigen, or antigen conjugated to a control mAb or delivered via DC-SIGN, another lectin receptor. Addition of Toll-like receptor (TLR) 7/8-agonist enhanced DCIR-mediated crosspresentation as well as crosspriming. Thus, antigen targeting via the human DCIR receptor allows activation of specific CD8+ T cell immunity.
-
6.发明授权THERAPEUTIC APPLICATIONS OF ACTIVATION OF HUMAN ANTIGEN-PRESENTING CELLS THROUGH DECTIN-1 有权细胞与人抗原的BY的Dectin-1的活化治疗应用
公开(公告)号：EP2129773B1
公开(公告)日：2013-02-13
申请号：EP08799678.1
申请日：2008-02-22
IPC分类号： C12N5/07 , A61K39/395 , C07K16/28
CPC分类号： C07K16/2851 , A61K39/395 , A61K2039/5154 , A61K2039/5158 , C07K16/1018 , C07K2317/24 , C07K2317/74 , C07K2317/92 , C07K2319/00 , C12N5/0639 , C12N9/2402 , C12N2501/22 , C12N2501/23 , C12N2501/50 , C12N2501/998
-
公开(公告)号：EP3388450A1
公开(公告)日：2018-10-17
申请号：EP18173658.8
申请日：2009-07-16
发明人： BANCHEREAU, Jacques F. , ZURAWSKI, Gerard , FLAMAR, Anne-laure , COBB, Amanda , MEAD, Holly , MONTES, Monica
CPC分类号： C07K14/005 , A61K39/12 , A61K39/21 , A61K47/646 , A61K47/6843 , A61K47/6849 , C07K16/2878 , C07K2319/01 , C07K2319/035 , C07K2319/30 , C07K2319/33 , C12N2740/16222 , C12N2740/16234 , C12N2740/16322 , C12N2740/16334
摘要： The present invention includes compositions and methods for making and using a vaccine that includes a DC-specific antibody or fragment thereof to which an engineered Gag antigen is attached to form an antibody-antigen complex, wherein the Gag antigen is less susceptible to proteolytic degradation by eliminating one or more proteolytic sites or a DC-specific antibody or fragment thereof to which an engineered Nef antigen is attached to form an antibody-antigen complex, wherein the Nef antigen comprises one or more codon usage optimization that increase antibody-antigen complex secretion, or both, wherein the vaccine is able to elicit an HIV-specific T cell immune response to Gag p17, Gag p24, Nef and/or Cyclin D1.
-
公开(公告)号：EP3094652A1
公开(公告)日：2016-11-23
申请号：EP15735460.6
申请日：2015-01-13
发明人： OH, Sangkon , ZURAWSKI, Sandra , ZURAWSKI, Gerard
IPC分类号： C07K16/28 , C07K16/08 , C07K16/46 , A61K39/12 , A61K39/395
CPC分类号： A61K39/12 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K2039/505 , A61K2039/53 , A61K2039/55511 , A61K2039/585 , A61K2039/6056 , A61K2039/70 , C07K14/005 , C07K16/2878 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2319/74 , C07K2319/91 , C12N7/00 , C12N2710/20034
摘要： Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV 16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines descirbed can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.
摘要翻译： 实施方案涉及针对人乳头状瘤病毒（HPV）和HPV相关疾病（包括多种类型的癌症）的新型疫苗。 HPV疫苗由抗人树突细胞（DC）表面受体抗体，包括HPV16和18的CD40和E6 / 7蛋白组成。所述技术不限于制备针对HPV16和HPV18相关疾病的疫苗， 可应用于从任何类型的HPV制备携带E6 / 7的疫苗。 描述的HPV疫苗可以靶向DCs，主要和专业抗原呈递细胞（APC），并且可以诱导和激活有效的HPV E6 / 7特异性和强的CD4 +和CD8 + T细胞应答。 HPV疫苗可用于预防HPV感染和HPV相关疾病以及用于治疗HPV相关疾病，包括癌症。
-
公开(公告)号：EP3091034A1
公开(公告)日：2016-11-09
申请号：EP16159238.1
申请日：2010-03-05
IPC分类号： C07K19/00 , C07K16/30 , C12N15/63 , C12N15/62 , A61K39/395 , A61P35/00 , C07K16/28 , A61K39/00 , C07K14/005
摘要： The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
摘要翻译： 本发明包括用于表达，分泌和使用用作例如疫苗和抗原递送载体的用于将抗原递送至抗原呈递细胞的组合物和方法。 在一个实施方案中，载体是抗CD40抗体或其片段，以及与抗CD40抗体或其片段（包括人源化抗体）连接的一个或多个抗原肽。
-
公开(公告)号：EP2406286B1
公开(公告)日：2016-05-18
申请号：EP10751218.8
申请日：2010-03-05
IPC分类号： C07K19/00 , C07K16/30 , C12N15/63 , C12N15/62 , A61K39/395 , A61P35/00 , C07K16/28 , A61K39/00 , C07K14/005
CPC分类号： C07K16/2878 , A61K39/00 , A61K2039/6056 , C07K14/005 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/74 , C07K2317/80 , C07K2319/00 , C12N2740/16222 , C12N2740/16322
-
-
-
-
-
-
-
-
-
搜索结果
37 条记录 (耗时 0.023 秒)
